Literature DB >> 16150582

In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size.

Chao Fang1, Bin Shi, Yuan-Ying Pei, Ming-Huang Hong, Jiang Wu, Hong-Zhuan Chen.   

Abstract

The aim of this study is to reveal the influence of methoxypolyethyleneglycol (MePEG) molecular weight and particle size of stealth nanoparticles on their in vivo tumor targeting properties. Three sizes (80, 170 and 240nm) of poly methoxypolyethyleneglycol cyanoacrylate-co-n-hexadecyl cyanoacrylate (PEG-PHDCA) nanoparticles loading recombinant human tumor necrosis factor-alpha (rHuTNF-alpha) were prepared at different MePEG molecular weights (MW=2000, 5000 and 10,000) using double emulsion method. The opsonization in mouse serum was evaluated by Coomassie brilliant blue staining of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Phagocytosis was evaluated by incubating (125)I-rHuTNF-alpha-loaded nanoparticles with mouse macrophages (RAW264.7). The pharmacokinetics, biodistribution and tumor targeting studies were performed in S-180 tumor-bearing mice. Higher MePEG molecular weight provided thicker fixed aqueous layer thickness (FALT) and smaller particle size offered higher surface MePEG density. The serum protein adsorption and phagocytic uptake were markedly decreased for the nanoparticles with higher MePEG molecular weight or smaller size. The particles (80nm) made of PEG(5000)-PHDCA, possessing a thicker FALT (5.16nm) and a shortest distance (0.87nm) between two neighboring MePEG chains, showed the strongest capacity of decreasing protein adsorption and phagocytic uptake. These particles extended the half-life of rHuTNF-alpha in S-180 tumor-bearing mice by 24-fold (from 28.2 min to 11.33 h), elevated the rHuTNF-alpha peak concentration in S-180 tumors by 2.85-fold and increased the area under the intratumoral rHuTNF-alpha concentration curve by 7.44-fold. The results of the present study showed PEG-PHDCA nanoparticles with higher MePEG molecular weight and smaller particle size could achieve higher in vivo tumor targeting efficiency.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16150582     DOI: 10.1016/j.ejps.2005.08.002

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  82 in total

Review 1.  Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance.

Authors:  William C Zamboni; Vladimir Torchilin; Anil K Patri; Jeff Hrkach; Stephen Stern; Robert Lee; Andre Nel; Nicholas J Panaro; Piotr Grodzinski
Journal:  Clin Cancer Res       Date:  2012-06-05       Impact factor: 12.531

2.  In vivo assembly of nanoparticle components to improve targeted cancer imaging.

Authors:  Steven D Perrault; Warren C W Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

Review 3.  Nanoparticles: a promising modality in the treatment of sarcomas.

Authors:  Michiro Susa; Lara Milane; Mansoor M Amiji; Francis J Hornicek; Zhenfeng Duan
Journal:  Pharm Res       Date:  2010-05-27       Impact factor: 4.200

Review 4.  Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution.

Authors:  Marina A Dobrovolskaia; Parag Aggarwal; Jennifer B Hall; Scott E McNeil
Journal:  Mol Pharm       Date:  2008-05-30       Impact factor: 4.939

Review 5.  Expert opinion: Responsive polymer nanoparticles in cancer therapy.

Authors:  William B Liechty; Nicholas A Peppas
Journal:  Eur J Pharm Biopharm       Date:  2011-08-25       Impact factor: 5.571

6.  Multiorgan chronic inflammatory hepatobiliary pancreatic murine model deficient in tumor necrosis factor receptors 1 and 2.

Authors:  Helieh S Oz
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

7.  Dysregulated TNFα promotes cytokine proteome profile increases and bilateral orofacial hypersensitivity.

Authors:  F Ma; L Zhang; H S Oz; M Mashni; K N Westlund
Journal:  Neuroscience       Date:  2015-05-29       Impact factor: 3.590

8.  Questioning the Use of PEGylation for Drug Delivery.

Authors:  Johan J F Verhoef; Thomas J Anchordoquy
Journal:  Drug Deliv Transl Res       Date:  2013-12       Impact factor: 4.617

9.  Multifunctional superparamagnetic iron oxide nanoparticles for combined chemotherapy and hyperthermia cancer treatment.

Authors:  Christopher A Quinto; Priya Mohindra; Sheng Tong; Gang Bao
Journal:  Nanoscale       Date:  2015-07-08       Impact factor: 7.790

Review 10.  Factors affecting the clearance and biodistribution of polymeric nanoparticles.

Authors:  Frank Alexis; Eric Pridgen; Linda K Molnar; Omid C Farokhzad
Journal:  Mol Pharm       Date:  2008-08-04       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.